Don't let poor solubility halt your drug's development....

At Synectix Pharmaceutical Solutions Ltd, we develop 'new generation' pharmaceutical and biopharmaceutical products using proprietary drug formulation and delivery technologies. These approaches are specifically applied to enhance the delivery and performance of poorly soluble, hydrophobic new chemical entities (NCEs) and late-stage development compounds showing poor bioavailability, as well as rescuing potential R&D drop-outs.

Our core research expertise is centered on the application of novel particle processing and 'drug activation' technologies to produce stable and soluble 'intermediates' for liquid, solid and semi-solid dosage forms. Using these proprietary technologies, we turn problematic drug candidates into easy to administer, stable and successful pharmaceutical products supporting preclinical profiling and early phase clinical studies.